Biofrontera (BFRI) Debt Ratio (2021 - 2024)

Biofrontera (BFRI) posted quarterly Debt Ratio of 0.01 for Q2 2024, down 85.68% quarter-over-quarter from 0.1 in Q1 2024.

Biofrontera (BFRI) Debt Ratio (2021 - 2024) Analysis & Trends

Biofrontera's Debt Ratio history runs 4 years deep, the most recent figure standing at 0.01 for Q2 2024.

In Q2 2024, Debt Ratio changed N/A year-over-year to 0.01; the TTM figure through Jun 2024 stood at 0.01 (changed N/A YoY), while the FY2023 annual figure was 0.14, up 2.45% from the prior year.
Debt Ratio for Q2 2024 stood at 0.01, down from 0.1 in the prior quarter.
The five-year high for Debt Ratio was 405.25 in Q4 2021, with the low at 0.01 in Q2 2024.
The 4-year median for Debt Ratio is 0.12 (2022), against an average of 50.74.
The sharpest annual moves came in 2022 and 2023: Debt Ratio plunged 99.97% in 2022, then increased 2.45% in 2023.
Biofrontera's Debt Ratio stood at 405.25 in 2021, then slumped by 99.97% to 0.14 in 2022, then gained by 2.45% to 0.14 in 2023, then tumbled by 90.18% to 0.01 in 2024.
Business Quant data shows BFRI's Debt Ratio at 0.01 in Q2 2024, 0.1 in Q1 2024, and 0.14 in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	44.23 Bn	43.26 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.82 Bn	40.16 Bn	2.15 Bn	0.42
3	Zoetis	32.64 Bn	30.96 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.64 Bn	22.84 Bn	5.10 Bn	0.32
5	United Therapeutics	22.38 Bn	19.71 Bn	683.80 Mn	-
6	Viatris	18.88 Bn	17.99 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn	-
8	Elanco Animal Health	11.96 Bn	11.43 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	0.12
10	Biofrontera	19.26 Mn	14.55 Mn	9.59 Mn	-

Download Data